Lv11
10 积分 2022-07-21 加入
Treatment of NSCLC after chemoimmunotherapy - are we making headway?
7小时前
已完结
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
7小时前
已完结
Adagrasib versus docetaxel in KRAS
7小时前
已完结
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
1年前
已完结
Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden
1年前
已完结
[Expert consensus on the diagnosis and treatment of anticancer drug-induced interstitial lung disease]
2年前
已完结
[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2022 edition)]
2年前
已完结
Cancer incidence and mortality in China, 2016
2年前
已完结
Allergic rhinitis
3年前
已完结
Allergic rhinitis
3年前
已完结
皖公网安备34019202002308
